GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » Degree of Financial Leverage

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Degree of Financial Leverage : -0.65 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Deciphera Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was -0.65. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Deciphera Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

DCPH's Degree of Financial Leverage is ranked better than
90.5% of 1042 companies
in the Drug Manufacturers industry
Industry Median: 0.97 vs DCPH: -0.65

Deciphera Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Deciphera Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Degree of Financial Leverage Chart

Deciphera Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only 0.61 0.22 0.71 1.29 -0.66

Deciphera Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.95 4.21 -0.66 -0.65

Competitive Comparison of Deciphera Pharmaceuticals's Degree of Financial Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals's Degree of Financial Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Degree of Financial Leverage falls into.



Deciphera Pharmaceuticals Degree of Financial Leverage Calculation

Deciphera Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.21 (Mar. 2024) / -2.35 (Mar. 2023) - 1 )/( -206.548 (Mar. 2024) / -189.087 (Mar. 2023) - 1 )
=-0.0596/0.0923
=-0.65***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Deciphera Pharmaceuticals  (NAS:DCPH) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Deciphera Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Executives
Jama Pitman officer: SVP, Regulatory & Quality C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin officer: Chief Commercial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly officer: Chief Financial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman officer: EVP & Chief Medical Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn officer: Chief Scientific Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc 10 percent owner 1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor director, officer: See Remarks C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen director C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl officer: Chief Business Officer C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer director C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066